Navigation Links
Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
Date:6/27/2012

BETHESDA, Md., June 27, 2012 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation applauds passage of a bill in the United States Senate to expand cooperation between the Food and Drug Administration (FDA) and outside rare disease experts and patient advocates during the FDA drug approval process.  

The bill, passed yesterday, is known as the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT). Its passage in the Senate is the last hurdle before the bill goes to President Obama for his signature. He is expected to sign it into law.

Introduced by Sen. Sheldon Whitehouse (D-RI),  EXPERRT is part of the FDA Safety and Innovation Act, which reauthorizes the FDA's user-fee program that funds its drug and device evaluation.

"The Cystic Fibrosis Foundation commends the Senate for its action on this issue, which is critical to the 30,000 Americans with cystic fibrosis and millions of others who struggle with complex conditions for which there are little or no available treatments," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation.  "Senator Whitehouse has been an invaluable champion for the CF community, and we are grateful to him for his work on this critical legislation." 

"I've heard from so many people with rare diseases who are frustrated with waiting for promising new treatments to gain approval, and who want to help speed up the process,"  said Whitehouse. "This bill accomplishes that goal by encouraging the FDA to take advantage of the wisdom and insights of rare disease experts and patient advocates in approving new treatments.  It's an important step toward providing faster access to promising new therapies, and I thank everyone who supported this bill for helping me to push it across the finish line."  

Passage of this legislation follows the recent approval of Kalydeco™, a cystic fibrosis drug developed by Vertex Pharmaceuticals with financial, scientific and clinical support from the Cystic Fibrosis Foundation.  Kalydeco's swift approval, announced by the FDA just three months after it was submitted for review, demonstrates how a well-informed, collaborative FDA review process involving reviewers, industry partners, patients and cystic fibrosis experts can efficiently move lifesaving therapies to market.  Kalydeco is the first CF drug to address the underlying cause of the disease in select CF patient groups.

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The Cystic Fibrosis Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Icahn Issues Statement Regarding Amylin Pharmaceuticals
2. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
3. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
4. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
6. Lilly Statement on PDUFA Vote by Senate
7. Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure
8. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
11. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... FRANCISCO , Feb. 11, 2016   Health ... advancement of new health technologies, announced today " 10 ... achievements in health tech over the past ten years.   ... For nearly a decade, Health 2.0 has served as ... showcased and connected with thousands of technologies, companies, innovators, ...
(Date:2/11/2016)... Feb. 11, 2016  MiMedx Group, Inc. (NASDAQ: ... amniotic membrane and other birth tissues, human skin and ... and market advanced products and therapies, announced today that ... Global Healthcare Conference in New York ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for ... General Hospital on April 5-7. The series is a multi-day, multi-workshop event designed ... workshops cover a broad range of topics, including coaching skills, the scientific method ...
(Date:2/12/2016)... Las Vegas, NV (PRWEB) , ... February 12, 2016 , ... ... of North Las Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott ... newest Fisher House at the VA Southern Nevada Healthcare System. This will be ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... southwest Houston and surrounding communities by continuing it’s commitment to act as Agents ... Promise. The organization works closely with area homeless families to fulfill immediate needs ...
Breaking Medicine News(10 mins):